Sign up USA
Proactive Investors - Run By Investors For Investors

Teva Pharmaceutical names Danish industry veteran Kare Schultz as its new chief executive

The new chief executive joins Teva - the world's biggest seller of generics medicines - from Denmark's H. Lundbeck A/S, where he has been president and CEO since May 2015
You're hired
He has also worked as chief operating officer of Novo Nordisk A/S, the world's biggest producer of insulin

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) has named industry veteran Kare Schultz as its new chief executive, ending a months-long period during which the Israeli firm had no permanent boss.

The new chief executive joins Teva - the world's biggest seller of generics medicines - from Denmark's H. Lundbeck A/S, where he has been president and CEO since May 2015.

He has also worked as chief operating officer of Novo Nordisk A/S, the world's biggest producer of insulin.

READ: Generic drugs giant Teva sinks after second quarter earnings disappoint, full-year guidance slashed

In a statement, Teva’s chairman Sol Barer said: “Kare has deep insight into the global pharmaceutical industry and a keen knowledge of the generic and specialty drug markets.

“His proven strategic, financial and operational capabilities and his strong commitment to growth will enhance value for all stakeholders and position Teva for long-term success.”

Teva has been searching for a new, permanent CEO since February, when former boss Erez Vigodman departed the company for undisclosed reasons. Yitzhak Peterburg has stood in as interim CEO since then.

There has been plenty of speculation about who might take the reins at Teva, with Pascal Soriot, CEO of AstraZeneca PLC (LON:AZN) at one stage cited as a contender.

Teva's shares in Tel Aviv rallied on news of the appointment, with its ADRs in New York gaining 11.3% to US$17.25 in pre-market trading.

View full TEVA profile View Profile

Teva Pharmaceutical Industries Timeline

Newswire
December 22 2016

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
researcher using microscope
September 28 2017
A total of £6mln is expected to come via a share placing and up to a further £2mln through an open offer of stock to existing investors

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use